OBJECTIVE: We analyzed the impact of potent anti-hypertension or anti-thrombotic therapy after PCI in patients with coronary heart disease complicated with hypertension, whilst to reflect the prognosis by testing P-selectin.
PATIENTS AND METHODS: A total of 177 patients with coronary heart disease (CHD) complicated with hypertension was continuously enrolled in this study and randomly divided into traditional anti-hypertension group (group A: 130/80 mm Hg ≤ BP ≤ 140/90 mm Hg; anti-hypertensive drugs: β blockers and angiotensin converting enzyme inhibitor, n=84) and potent anti-hypertension group (group B: BP <130/80 mm Hg; dosage and frequency in group B > group A, n=93). This study was approved by the Ethics Committee of Shaoxing People’s Hospital. Signed written informed consents were obtained from all participants before the study. Patients who need a stent placed (CAG shows narrowed vascular diameter ≥75%) have to continuously be followed-up for one year. Standard anti-hypertension (fluctuation of BP <5 mm Hg measured for 3 successive days) was detected respectively at admission and inpatient. The blood pressure, low-density lipoprotein cholesterin (LDL-C), high-sensitivity C-reactive protein (hs-CRP) and P-selectin levels were tested 1 month and 1 year after discharge; the time of adverse events (AEs) was also recorded.
RESULTS: There were no statistical differences between the occurrence times of AEs between group A and B (p=0.946). The P-selectin [(83±21) vs. (69±16) μg/L, p=0.038], systolic pressure [(134±8) vs. (119±13) mm Hg, p<0.001] and diastolic pressure [(85±6) vs. (70±5) mm Hg] in group A were higher (p=0.001) than those of group B. Compared with P-selectin ≥50.00 μg/L, the median survival time (>12 vs. 10 months, χ2=3.621, p=0.047) of P-selectin <50.00 μg/L was longer. By comparing P-selectin in different SBP grading (<120 mm Hg, 120-130 mm Hg, 130-140 mm Hg), the difference was statistically significant (χ2=12.912, p=0.002).
CONCLUSIONS: Potent anti-hypertension may influence the occurrence time of AEs after PCI in patients with coronary heart disease complicated hypertension. P-selectin can be a sensitive indicator. SBP has an apparent “J-curve effect” and an appropriate anti-hypertensive scope (120-130 mm Hg).Free PDF Download
To cite this article
F.-F. Yang, F. Peng, Y.-B. Xing, M. Yuan, X.-C. Ma, G. Li, H.-Y. Guo
Impacts of serum P-selectin on blood pressure control after PCI in patients with coronary heart disease complicated with hypertension
Eur Rev Med Pharmacol Sci
Vol. 21 - N. 3 Suppl